We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

DOJ Teaches a Lesson in Healthcare Marketing

01 June 2006

Inside Litigation

In a major enforcement strategy shift, the U.S. Department of Justice (DOJ) has taken firm control of enforcement against pharmaceutical and biotech manufacturers. Both "Main Justice" in Washington and various U.S. Attorney Offices around the country now enforce against pharmaceutical companies through not only the Food, Drug, and Cosmetic Act, but also the Anti-Kickback statute and the False Claims Act.


Loading data